Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity

Arthritis and Rheumatism

Volumn 43, Issue 5, 2000, Pages 1041-1048

  Weyand, Cornelia M ^a   Fulbright, James W ^a   Hunder, Gene G ^a   Evans, Jonathan M ^a   Goronzy, Jörg J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GIANT CELL ARTERITIS; HUMAN; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TEMPORAL ARTERITIS;

EID: 0034081799     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7     Document Type: Article

References (43)

1. Weyand CM, Goronzy JJ. Polymyalgia rheumatica and giant cell arteritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams & Wilkins. In press.
2. Hunder GG. Giant cell (temporal) arteritis. Rheum Dis Clin North Am 1990;16:399-409.
3. Ghanchi FD, Dutton GN. Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol 1997;42:99-123.
4. Weyand CM, Bartley GB. Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 1997;123:392-5.
5. Kyle V. Treatment of polymyalgia rheumatica/giant cell arteritis. Baillieres Clin Rheumatol 1991;5:485-91.
6. Bengtsson BA, Andersson R. Giant cell and Takayasu's arteritis. Curr Opin Rheumatol 1991;3:15-22.
7. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: results in 55 cases in which lesion was proven at biopsy. JAMA 1957;163:821-7.
8. Ghanchi FD, Williamson TH, Lim CS, Butt Z, Baxter GM. McKillop G, et al. Colour Doppler imaging in giant cell (temporal) arteritis: serial examination and comparison with non-arteritic anterior ischaemic optic neuropathy. Eye 1996;10:459-64.
9. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994;120:987-92.
10. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997;99:2842-50.
11. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
12. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997;3:530-43.
13. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis: evidence for two components of the disease. J Clin Invest 1994;94:1134-40.
14. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992;127:25-50.
15. Kushner I, Rzewnicki DL. The acute phase response: general aspects. Baillieres Clin Rheumatol 1994;8:513-30.
16. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990;29:456-8.
17. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
18. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
19. Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996;35:1161-8.
20. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997;123:285-96.
21. Ellis JD, Munro P, McGettrick P. Blindness with a normal erythrocyte sedimentation rate in giant cell arteritis. Br J Hosp Med 1994;52:358-9.
22. Zweegman S, Makkink B, Stehouwer CD. Giant-cell arteritis with normal erythrocyte sedimentation rate: case report and review of the literature. Neth J Med 1993;42:128-31.
23. Cid MC, Monteagudo J, Oristrell J, Vilaseca J, Pallares L, Cervera R, et al. Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 1996;55:927-30.
24. Pountain GD, Calvin J, Hazleman BL. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994;33: 550-4.
25. Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;98:1642-9.
26. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999;42:844-53.
27. Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989;48:667-71.
28. Evans JM, Batts KP, Hunder GG. Persistent giant cell arteritis despite corticosteroid treatment. Mayo Clin Proc 1994;69:1060-1.
29. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577-84.
30. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971;285:1493-6.
31. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
32. Hoffman GS. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum 1997;40:2099-104.
33. Langford CA, Sneller MC. New developments in the treatment of Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Curr Opin Rheumatol 1997;9:26-30.
34. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/ polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8.
35. Feinberg HL, Sherman JD, Schrepferman CG, Dietzen CJ, Feinberg GD. The use of methotrexate in polymyalgia rheumatica. J Rheumatol 1996;23:1550-2.
36. Van der Veen M, Dinant H, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23.
37. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989;48:662-6.
38. Evans JM, Bowles CA, Bjornsson J, Mullany CJ, Hunder GG. Thoracic aortic aneurysm and rupture in giant cell arteritis: a descriptive study of 41 cases. Arthritis Rheum 1994;37:1539-47.
39. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995;122:502-7.
40. Andersson R, Rundgren A, Rosengren K, Bengtsson BA, Malmvall BE, Mellstrom D. Osteoporosis after long-term corticosteroid treatment of giant cell arteritis. J Intern Med 1990;227:391-5.
41. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
42. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-7.
43. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.